Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

L.A. McKeown

February 04, 2026

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Opinion CV Team Dispatch

September 2023 News Roundup

L.A. McKeown

September 01, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Opinion CV Team Dispatch

December 2022 News Roundup

L.A. McKeown

December 28, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

L.A. McKeown

December 24, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

Advertisement

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

December 2025 Dispatch for the CV Team

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Scientific Statement Reviews Current Antithrombotic Options in PAD

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

Top Endovascular News of 2023

September 2023 News Roundup

Only Half of Revascularized PAD Patients Receive GDMT

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

December 2022 News Roundup

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

September 2021 News Roundup

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content